Education
About Us
Working with TipRanks
Follow Us
Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
RESEARCH TOOLSreports
ACRV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $10.29
Previous CloseN/A
Volume1.72K
Average Volume (3M)290.88K
Market Cap
$63.64M
Enterprise Value$54.38M
Total Cash (Recent Filing)$99.60M
Total Debt (Recent Filing)$5.63M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 13, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding31,351,480
10 Day Avg. Volume395,033
30 Day Avg. Volume290,884
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1245.45
Price to Cash Flow (P/CF)-2.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.64
Forecast
1Y Price Target
$12.33Price Target Upside507.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Acrivon Therapeutics, Inc. News
PremiumCompany Announcements
Acrivon Therapeutics Reports Progress in Cancer Drug Development
PremiumCompany Announcements
Acrivon Therapeutics Appoints New Chief Medical Officer---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsData in endometrial cancer shows strong clinical benefits, with a 35% overall response rate and 80% disease control rate.
Competitive PositionThe ACR-368 update demonstrates a competitive profile in mEC, providing a promising option where not many exist.
Financial PositionThe company has a strong cash balance of $185M, projected to support operations into 2027.
Bears Say
Financial RisksThe need for approximately $300M additional financing through 2038 poses a financial risk.
Product Launch DelaysThe launch in endometrial cancer has been pushed back to 2028 from 2027, and the technology value has been reduced.
Program DeprioritizationAcrivon is deprioritizing its ovarian and bladder cancer programs due to challenges in patient recruitment and higher efficacy expectations.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.30 and its highest was $10.29 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $63.64M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is May 13, 2025 which is in 19 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.6 earnings per share for the quarter, beating the consensus estimate of -$0.664 by $0.064.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 31,351,480 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.6 in its last earnings report, beating expectations of -$0.664. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
---
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (507.39% Upside)
$12.33 (507.39% Upside)
Blogger Sentiment
Bullish
ACRV Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.65%
12-Months-Change
Fundamentals
Return on Equity
-54.07%
Trailing 12-Months
Asset Growth
42.18%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
---
ACRV Stock 12 Month Forecast
Average Price Target
$12.33
▲(507.39% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Bluebird Bio
―
Avalo Therapeutics
―
Sutro Biopharma
―
Fractyl Health, Inc.
―
Best Analysts Covering ACRV
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-29.64%
reiterated a buy rating 24 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -29.64% per trade.
---